Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: Outcomes from the ACS NSQIP database

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1494-1500

  Bartlett, Edmund K ^a   Meise, Chelsey ^a   Roses, Robert E ^a   Fraker, Douglas L ^a   Kelz, Rachel R ^a   Karakousis, Giorgos C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BILIRUBIN;

ADULT; AGE; ARTICLE; ASCITES; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CHOLECYSTECTOMY; COLON RESECTION; CYTOREDUCTIVE SURGERY; DATA BASE; DIAPHRAGM; FEMALE; GASTRECTOMY; HEMATOCRIT; HUMAN; INTRAPERITONEAL CHEMOTHERAPY; LENGTH OF STAY; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEPHRECTOMY; OPERATION DURATION; PATIENT HISTORY OF SURGERY; PATIENT SELECTION; PERITONEUM; PERITONEUM PSEUDOMYXOMA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; SEPSIS; SMALL INTESTINE RESECTION; SPLENECTOMY; SURGICAL INFECTION; SURGICAL MORTALITY; THORAX SURGERY; WEIGHT REDUCTION; WOUND ASSESSMENT; CANCER STAGING; COHORT ANALYSIS; FACTUAL DATABASE; FOLLOW UP; HYPERTHERMIC THERAPY; MEDICAL SOCIETY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; PROGNOSIS; REGIONAL PERFUSION; RISK FACTOR; SURVIVAL RATE; TOTAL QUALITY MANAGEMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COHORT STUDIES; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM STAGING; NEOPLASMS; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUALITY IMPROVEMENT; RISK FACTORS; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 84898922099     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3223-z     Document Type: Article

References (28)

1. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg. 1989;32:164-70. (Pubitemid 19152802)
2. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449-56.
3. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863-9. (Pubitemid 40486849)
4. Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144-53.
5. Levine EA, Stewart JHt, Russell GB, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204:943-53. (Pubitemid 46661217)
6. Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94:1408-14. (Pubitemid 350144391)
7. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635-44.
8. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-81.
9. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426-32.
10. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-43. (Pubitemid 46606227)
11. Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518-21. (Pubitemid 40486734)
12. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900-7.
13. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790-6. (Pubitemid 30013658)
14. Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol. 2008;15:754-63.
15. Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg. 2012;255:348-56.
16. American College of Surgeons National Surgical Quality Improvement Program. http://site.acsnsqip.org/.
17. Americal College of Surgeons National Surgical Quality Improvement Program. User guide for the 2010 participant use data file. http://site. acsnsqip.org/wp-content/uploads/2012/03/2010-User-Guide-FINAL.pdf.
18. Daley J, Forbes MG, Young GJ, et al. Validating risk-adjusted surgical outcomes: site visit assessment of process and structure. National VA Surgical Risk Study. J Am Coll Surg. 1997;185:341-51. (Pubitemid 27419191)
19. Raval MV, Hamilton BH, Ingraham AM, et al. The importance of assessing both inpatient and outpatient surgical quality. Ann Surg. 2011;253:611-8.
20. Shiloach M, Frencher SK Jr, Steeger JE, et al. Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg. 2009;210:6-16.
21. StataCorp. Stata/IC 12.0 statistical software. College Station, TX: StataCorp; 1985-2011. http://www.stata.com.
22. Circle Systems. Stat/Transfer: version 11. Seattle, WA: Circle Systems Inc.; 2011.
23. Juul SFM. An introduction to Stata for health researchers. III ed. College Station, TX: StataCorp; 2010. p. 179-96.
24. Aloia TA, Fahy BN, Fischer CP, et al. Predicting poor outcome following hepatectomy: Analysis of 2313 hepatectomies in the NSQIP database. HPB (Oxford). 2009;11:510-5.
25. Greenblatt DY, Kelly KJ, Rajamanickam V, et al. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol. 2011;18:2126-35.
26. Grossmann EM, Longo WE, Virgo KS, et al. Morbidity and mortality of gastrectomy for cancer in Department of Veterans Affairs medical centers. Surgery. 2002;131:484-90. (Pubitemid 34478493)
27. Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692-8.
28. Piso P, Slowik P, Popp F, et al. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:2188-94.